Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma
- PMID: 37898721
- PMCID: PMC10781745
- DOI: 10.1038/s41416-023-02458-w
Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma
Abstract
Adenocarcinoma of the oesophagus and gastro-oesophageal junction represent a large burden of cancer death in the Western World with an increasing incidence. In the past two decades, the overall survival of patients on a potentially curative treatment pathway has more than doubled due to the addition of perioperative oncological therapies to surgery. However, patients often fail to respond to oncological treatment or struggle to complete their treatment after surgery. In this review, we discuss the current evidence for total neoadjuvant therapy and options for assessment of treatment response.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
References
-
- Cancer Research UK. Oesophageal cancer statistics. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/s....
-
- Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57. doi: 10.1016/S0140-6736(18)32557-1. - DOI - PubMed
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources